Chase Partners Again, Looks at Medical Sector –

In the latest joint venture between Chase Capital Partners (CCP) and an industry specialist, the New York-based group has partnered with Charles Orsatti to form Fairfield Chase Medical Partners L.L.C., an investment entity focused on buyouts of middle-market medical product companies.

Chase capitalized the new venture with $50 million in equity, and Mr. Orsatti, who has 30 years of experience in the investments that focus on the medical device sector, particularly surgical, anesthetic and pulmonary monitoring equipment. Mr. Orsatti has focused on these areas throughout his career, which has included service with domestic and international medical companies including British Oxygen Corp., Johnson & Johnson Corp., Critikon Corp. and Coloplast Inc.

“We want to create a sort of branding where owners are selling to a financial buyer that has an operating individual,” said Damion Wicker, a CCP general partner who is working on the effort.

Investments will be structured with equity components of as much as $50 million and will employ significant leverage.

The group has contracted Charlotte, N.C.-based Bowles Hollowell Conner & Co. to formally research acquisition candidates, Mr. Orsatti said.

Prior CCP team-ups include Cassandra Chase Entertainment Partners, which targets the entertainment industry, and IMG/Chase Sports Capital, which focuses on sports related companies.